Research programme: purinoceptor P2U agonists - EPIX

Drug Profile

Research programme: purinoceptor P2U agonists - EPIX

Alternative Names: EPX-16006; MDT-006

Latest Information Update: 13 Jun 2014

Price : $50

At a glance

  • Originator EPIX Pharmaceuticals
  • Developer Cystic Fibrosis Foundation Therapeutics; EPIX Pharmaceuticals; MicroDose Therapeutx
  • Class Small molecules
  • Mechanism of Action Purinoceptor P2U agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Preclinical Constipation; Irritable bowel syndrome
  • Discontinued Cystic fibrosis

Most Recent Events

  • 08 Jul 2013 MicroDose Therapeutx has been acquired by Teva Pharmaceutical Industries
  • 17 Nov 2010 Preclinical development is ongoing in USA
  • 05 Nov 2010 MicroDose Therapeutx receives a Therapeutic Discovery Project grant from the US Internal Revenue Service for MDT 006 development in Gastrointestinal disorders
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top